SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma

References

• Yang Y, Li Y, Gu H, et al. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13:150.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64:422–444.
   PubMedGoogle Scholar
• Ninkovic S, Quach H. Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview. Cancers. 2020;12(11):3488.
   PubMedGoogle Scholar
• John L, Krauth MT, Podar K, et al. Pathway-directed therapy in multiple myeloma. Cancers. 2021;13:1668.
   PubMedGoogle Scholar
• Boyle EM, Ashby C, Tytarenko RG, et al. BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma. Clin Cancer Res. 2020;26(10):2422–2432.
   PubMedGoogle Scholar
• Sharman JP, Chmielecki J, Morosini D, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(5):e161–e163.
   PubMedGoogle Scholar
• Mey UJM, Renner C, von Moos R. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. Hematol Oncol. 2017;35(4):890–893.
   PubMed Web of Science ®Google Scholar
• Raje N, Chau I, Hyman DM, et al. Vemurafenib in patients with relapsed refractory multiple myeloma harboring BRAF V600 mutations: a cohort of the histology-independent VE-BASKET study. J Clin Oncol Precis Oncol. 2018;2(2):1–9.
   Google Scholar
• Conti D, Gul P, Islam A, et al. Kinetochores attached to microtubule-ends are stabilised by astrin bound pp1 to ensure proper chromosome segregation. Elife. 2019;8:1–28.
   Google Scholar
• Gholkar AA, Senese S, Lo YC, et al. The X-linked-intellectual-disability-associated ubiquitin ligase Mid2 interacts with astrin and regulates astrin levels to promote cell division. Cell Rep. 2016;14(2):180–188.
   PubMedGoogle Scholar
• He J, Green AR, Li Y, et al. SPAG5: an emerging oncogene. Trends Cancer. 2020;6(7):543–547.
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TMA, Agarwal D, Liu DX, et al. SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncol. 2016;17(7):1004–1018.
   PubMed Web of Science ®Google Scholar
• Yuan LJ, Li JD, Zhang L, et al. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis. 2014;5(5):e1784.
   Google Scholar
• Wang C, Su H, Cheng R, et al. SPAG5 is involved in human gliomagenesis through the regulation of cell proliferation and apoptosis. Front Oncol. 2021;11:673780.
   PubMedGoogle Scholar
• Ying Z, Yang J, Li W, et al. Astrin: a key player in mitosis and cancer. Front Cell Dev Biol. 2020;8:1–8.
   PubMedGoogle Scholar
• Liu JY, Zeng QH, Cao PG, et al. SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. Oncogene. 2018;37(29):3937–3952.
   PubMedGoogle Scholar
• Navarro Gonzalez J, Zweig AS, Speir ML, et al. The UCSC genome browser database: 2021 update. Nucleic Acids Res. 2021;49(D1):D1046–D1057.
   PubMed Web of Science ®Google Scholar
• Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625–634.
   PubMed Web of Science ®Google Scholar
• Tricot G, Rasmussen E, Anaissie E, et al. Total therapy 2 (TT2) for multiple myeloma (MM): thalidomide (T) effects superior complete response (CR) and event-free survival (EFS); similar overall survival (OS) linked to shorter post-relapse survival. Blood. 2005;106(11):423.
   Google Scholar
• Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21(43):6587–6597.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Fujiwara S, Wada N, et al. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012;41(3):876–884.
   PubMedGoogle Scholar
• Hsu JH, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98(9):2853–2855.
   PubMed Web of Science ®Google Scholar
• Lee SR, Park JH, Park EK, et al. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol. 2005;205(2):270–277.
   PubMedGoogle Scholar
• David E, Sun SY, Waller EK, et al. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood. 2005;106(13):4322–4329.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107(10):4053–4062.
   PubMed Web of Science ®Google Scholar
• Spencer A, Yoon SS, Harrison SJ, et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014;124(14):2190–2195.
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhang MF, Tian QH, et al. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma. Mol Cancer. 2018;17(1):1–13.
   PubMedGoogle Scholar
• Thedieck K, Holzwarth B, Prentzell MT, et al. Inhibition of mTORC1 by astrin and stress granules prevents apoptosis in cancer cells. Cell. 2013;154(4):859–874.
   PubMedGoogle Scholar
• Liu G, Liu S, Cao G, et al. SPAG5 contributes to the progression of gastric cancer by upregulation of survivin depend on activating the Wnt/β-catenin pathway. Exp Cell Res. 2019;379(1):83–91.
   PubMed Web of Science ®Google Scholar
• Li M, Li A, Zhou S, et al. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol. 2019;12(1):1–18.
   PubMedGoogle Scholar
• Canu V, Donzelli S, Sacconi A, et al. Aberrant transcriptional and post-transcriptional regulation of SPAG5, a Yap-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. Cell Death Differ. 2021;28(5):1493–1511.
   PubMedGoogle Scholar
• Liu J, Zhang Y, Zeng H, et al. Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancer. J Nanobiotechnology. 2021;19:189.
   PubMed Web of Science ®Google Scholar